Table 2 Association of genetically predicted age at menarche with CRC risk according to subgroups, CCFR, GECCO Consortium

From: Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer

Subgroup

N (cases/controls)

ORa

95% CI

P-value

Heterogeneity P-valueb

All

5832/6285

0.97

0.92–1.02

0.20

 

Menopausal status

Premenopausal

545/621

0.95

0.80–1.12

0.54

0.94

Postmenopausal

5263/5647

0.97

0.92–1.02

0.23

 

Menopausal hormone therapy combined

No

3266/3490

0.96

0.90–1.03

0.24

0.69

Yes

593/807

0.98

0.85–1.14

0.82

 

Oestrogen monotherapy

No

3120/3214

0.94

0.88–1.01

0.11

0.17

Yes

716/1088

1.04

0.91–1.19

0.55

 

Site

Colon

4037/6285

0.97

0.91–1.02

0.26

0.25c

Rectum

1184/6285

1.04

0.95–1.14

0.36

 
  1. CCFR Colon Cancer Family Registry, CI confidence interval, GRS genetic risk score, OR odds ratio per year
  2. aAll analyses adjusted for age, sex, study, and principal components of genetic ancestry
  3. bP-value calculated using likelihood ratio tests comparing the model with and without interaction term
  4. cP-value for heterogeneity was obtained in case-only analysis of colon vs. rectal cancer
Back to article page